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Despite the wide use of the oral route to deliver systemic drugs to humans, the intestinal absorption pro-
cess is still not fully understood. Especially for complex absorption-enabling strategies (e.g. solubiliza-
tion, supersaturation, etc.), the in vivo performance is difficult to predict. Considering the current
share of drug candidates that suffer from a non-favorable absorption potential and therefore rely on these
strategies, there is a growing interest in approaches that aim to resolve the multitude of interactions
between drugs, formulation factors and the gastrointestinal environment. In this respect, gastrointestinal
concentration profiling following drug administration to humans is a recent but promising strategy that
complements more established techniques including gastrointestinal imaging. In the present review, a
number of case studies will be discussed to demonstrate the added value of gastrointestinal concentra-
tion profiling to gain in-depth knowledge of intraluminal drug and formulation behavior and to identify
those processes key for drug absorption. Examples include a better understanding of intestinal precipita-
tion of weakly basic drugs, clarifying inter-individual or food-induced variability in absorption, and an
improved insight into the solubility-permeability interplay. As manifested in a recently initiated Euro-
pean project on oral biopharmaceutics tools (OrBiTo), intraluminal concentration profiling will contribute
to the development of relevant simulation models that are built upon a solid understanding of human
drug and formulation behavior, and allow for a more predictive in vitro and in silico evaluation of
absorption.
 2014 Elsevier B.V. All rights reserved.1. Introduction
Impaired intestinal absorption, causing insufficient or variable
bioavailability, is one of the key reasons for suboptimal clinical
performance of orally administered drugs with systemic action.
Reliable preclinical prediction of absorption during drug candidate
selection and formulation development is of paramount impor-
tance to tackle absorption issues and reduce drug attrition during
clinical trials. Classically, in vitro evaluation of absorption involves
assessment of the drug’s absorption potential (i.e. solubility and
permeability) and, in the course of formulation development, dis-
solution in static, one compartment setups (USP apparatus I and
II). While these approaches may suffice to forecast uptake of easily
absorbed molecules, they are less accurate as in vivo predictive
tools for molecules with less favorable absorption potential (i.e.
limited solubility and/or permeability). Enabling absorption ofthese compounds requires sometimes challenging formulation
strategies of which the performance greatly depends on the gastro-
intestinal physiology and the interplay between multiple pro-
cesses, as schematically represented in Fig. 1. Attempts to
capture this interplay in biorelevant in vitro evaluation tools have
resulted in the development of dynamic, multicompartmental sys-
tems to account for time-dependent fluid composition, gastroin-
testinal transit and/or permeation (e.g. USP apparatus IV,
dissolution-permeation system, TNO Intestinal Model) (McAllister,
2010). In addition, computational physiologically based models
have been anticipated as powerful tools to integrate in vitro data
and simulate the human absorption process (physiology-based
(PBPK) pharmacokinetic modeling) (Kostewicz et al., in press).
For many drug-formulation combinations, however, the predictive
power of these models still appears either insufficient or uncertain
(Kostewicz et al., in press).
Further model optimization is often impeded by gaps in the
knowledge on the in vivo behavior of complex formulations in
the gastrointestinal tract. An example that currently receives much
attention is the precipitation of drugs in the stomach or intestine.
Since the induction of intraluminal supersaturation has recentlyon pro-
Fig. 1. Schematic and simplified representation of intraluminal processes determining intestinal absorption.
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to enable absorption of poorly soluble drugs, assessment of possi-
ble precipitation prior to drug uptake is crucial to evaluate the po-
tential of supersaturating drug delivery systems. However, the
knowledge on in vivo precipitation in the gastrointestinal tract is
nearly non-existing and recent studies suggest that most in vitro
simulations of precipitation are inaccurate (Bevernage et al.,
2013). To overcome these types of obstacles, reference studies that
assess the intraluminal fate of drugs and dosage forms in humans
are receiving intensified attention. This has recently been mani-
fested within the Oral Biopharmaceutics Tools (OrBiTo) project.
OrBiTo, a new project within the Innovative Medicines Initiative
(IMI) between the European Union and the European Pharmaceu-
tical Industry Association (EFPIA), pursues the development of no-
vel, in vivo predictive experimental and theoretical models for oral
absorption (Lennernäs et al., in press). One of the main pillars of
OrBiTo is a thorough understanding of the absorption process that
should support these novel tools.
In this framework, the present review aims to demonstrate the
assessment of gastrointestinal concentrations upon oral drug
administration as a recent tool to evaluate intraluminal drug and
formulation behavior in humans and to guide the optimization of
simulation models.2. Evaluating gastrointestinal drug and formulation behavior in
humans
Traditionally, the development of in vitro models that aim to
simulate intestinal drug absorption is driven by reference data
from classic pharmacokinetic studies. This implies, at best, indirect
assessment of the underlying intraluminal processes through mod-
eling of systemic concentration–time profiles using, for instance,
deconvolution or PBPK modeling. It has been recognized that only
direct evaluation of the intraluminal behavior allows for an in-
depth understanding of the complex interplay between gastroin-
testinal physiology and drug formulations. For this purpose, both
imaging and intubation techniques can be used.
2.1. Imaging techniques
Imaging of the gastrointestinal tract allows for a non-invasive
way to follow the fate of orally administered dosage forms without
disturbing physiological processes. The historical gold standard is
gamma scintigraphy, but more recently, alternative approaches
have been introduced based on magnetic tracking principles. InPlease cite this article in press as: Brouwers, J., Augustijns, P. Resolving intralu
filing in humans. Eur. J. Pharm. Sci. (2014), http://dx.doi.org/10.1016/j.ejps.201this paper, the different techniques, including their strengths and
weaknesses, are only shortly raised; for a detailed discussion, we
refer to recent reviews on this topic (Corá et al., 2011; Weitschies
and Wilson, 2011; Weitschies et al., 2010).
Gamma scintigraphy has been applied to investigate the gastro-
intestinal behavior of pharmaceutical dosage forms since 1976
(Casey et al., 1976; Wilding et al., 2001). In this method, a dosage
form is labeled with a gamma-emitting radioisotope, either by di-
rect incorporation during formulation (99mTc or 111In) or by neu-
tron activation of a stable isotope (e.g. 152Sm, activated to 153Sm).
Subsequently, the distribution of these isotopes in the gastrointes-
tinal tract can be assessed by means of a scintillation camera,
which generates a two-dimensional projected view. This allows
monitoring the intraluminal location of the labeled dosage form
(transit) and its integrity (release) over the entire length of the gas-
trointestinal tract. The approach has been used to evaluate the res-
idence time in the stomach, small intestine and colon in different
conditions (e.g. fasted versus fed state). Furthermore, the combina-
tion of scintigraphy with pharmacokinetic studies (pharmacoscin-
tigraphy) has become an important means of increasing insight
into the impact of transit and release of oral dosage forms on drug
absorption.
The main disadvantage of scintigraphy is the necessity to apply
ionizing radiation, requiring essential precautions and regulatory
issues. Alternative imaging techniques that avoid this type of strain
to volunteers and investigators are based on the detection of mag-
netically labeled dosage forms (Corá et al., 2011), including the
method of magnetic marker monitoring (MMM) (Weitschies
et al., 2010). For MMM, the dosage form is marked as a permanent
magnetic dipole by the incorporation of ferromagnetic material
and subsequent magnetization in a strong magnetic field. After oral
administration, the three dimensional localization of the dosage
form (i.e. the magnetic source) in the gastrointestinal tract can
be monitored as a function of time. Compared to scintigraphy,
the high temporal (real-time) and spatial (1 mm) resolution of
MMM allows for a more detailed insight into gastrointestinal tran-
sit. In addition, disintegration of the dosage form can be quantita-
tively monitored, as it is related to a decrease in magnetic strength.
Once released, however, particles cannot be visualized anymore.2.2. Intubation techniques
Catheters introduced through the nose, mouth or rectum allow
for direct access to the contents of the gastrointestinal tract of hu-
man volunteers. Apart from aspirating gastric and intestinal fluidsminal drug and formulation behavior: Gastrointestinal concentration pro-
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fluids, intubation enables monitoring drug concentrations in gas-
trointestinal fluids to study absorption processes. Initial studies fo-
cused on distinct processes (e.g. absorption, dissolution,
metabolism) by perfusing an intestinal segment with a drug solu-
tion or suspension. This approach was illustrated for the first time
by Jobin et al. (1985). Using multi-lumen tubes, a drug solution
was perfused in different regions of the intestinal tract. Drug
absorption was monitored based on the disappearance of the drug
from aspirated intestinal fluid and the appearance in blood. A sim-
ilar but refined approach is the Loc-I-Gut perfusion method, orig-
inally proposed to investigate the permeation of drugs across the
intestinal epithelium in vivo (Knutson et al., 1989, 2009). In this
technique, one multi-lumen tube is used; two latex balloons are in-
flated in order to isolate an intestinal segment that is subsequently
perfused with a drug solution. Permeability is calculated from the
disappearance of drug during perfusion. This approach has become
the standard method to determine human intestinal permeability
(Lennernäs, 1998). The Loc-I-Gut method also allows assessing
intestinal drug metabolism and luminal excretion (Petri et al.,
2003; Tannergren et al., 2003), and performing in vivo dissolution
tests when the segment is perfused with a drug suspension
(Bønløkke et al., 1997). Observed differences between in vitro
and in vivo dissolution of drugs indicate the impact of the complex
and dynamic gastrointestinal environment (Bønløkke et al., 1999,
2001).
In 2005, Brouwers et al. investigated the intraluminal behavior
of two theophylline formulations in healthy volunteers by deter-
mining drug concentrations in simultaneously aspirated duodenal
and jejunal fluids (Brouwers et al., 2005). For the first time, intra-
luminal drug concentrations were monitored as a function of time
upon oral drug intake in humans. Since then, additional studies
with more challenging drugs and formulations have been per-
formed, illustrating that this approach offers a unique way to gain
insight into intraluminal dosage form performance and subsequent
drug absorption. In the following sections of this review, we will
discuss the methodology and the added value of monitoring intra-
luminal drug concentrations in humans to understand gastrointes-
tinal formulation behavior and to guide optimization of simulation
models.3. Gastrointestinal concentration profiling upon drug
administration in humans: methodology
The assessment of gastrointestinal drug concentrations in hu-
mans is schematized in Fig. 2. This section comprises a brief
description of different methodological aspects involved in this
type of clinical studies.3.1. Intubation of healthy volunteers
In all studies reported so far, fluids were aspirated from the
upper gastrointestinal tract of healthy volunteers. In one study,
the previously mentioned Loc-I-Gut catheter was employed to
aspirate fluids from a semi-open intestinal segment (created by
inflating the distal balloon of the catheter) (Bergman et al.,
2007). Other studies sampled from open segments, making use of
standard double-lumen catheters designed to aspirate gastric and
intestinal fluids in clinical practice. The catheters are introduced
via the mouth or nose and positioned into the stomach (usually an-
trum), duodenum or proximal jejunum. Positioning is guided by a
wire and checked by means of fluoroscopy (X-rays). This implies
that this type of study cannot be performed in pregnant women
or children. In a number of studies, two double-lumen catheters
have been used to simultaneously assess drug concentrations atPlease cite this article in press as: Brouwers, J., Augustijns, P. Resolving intralu
filing in humans. Eur. J. Pharm. Sci. (2014), http://dx.doi.org/10.1016/j.ejps.201two intraluminal positions: duodenum and jejunum (Brouwers
et al., 2005, 2006), or stomach and duodenum (Brouwers et al.,
2007a; Walravens et al., 2011). The latter positioning is shown in
the X-ray picture in Fig. 3.
In contrast to imaging techniques, intubation studies are inva-
sive and may, as such, disturb the gastrointestinal physiology. A
number of reports, however, indicated only minor or non-signifi-
cant effects of transpyloric tubes on gastric emptying, gastric
secretions and duodenogastric reflux (Go et al., 1970; Longstreth
et al., 1975; Näslund et al., 2000; Read et al., 1983; Rees et al.,
1979). Read et al. (1983) did observe a significant reduction in
the small intestinal transit time but this may be related to the
use of a long tube, reaching the terminal ileum.
3.2. Dosage form administration
Drugs are administered either orally (dosage form with water)
(Brouwers et al., 2005, 2006, 2007a; Walravens et al., 2011) or di-
rectly into the stomach by means of a catheter (solution or suspen-
sion) (Bergman et al., 2007; Psachoulias et al., 2011; Vertzoni et al.,
2012). Obviously, ‘real-life’ administration is most relevant, but
gastric dosing may be more appropriate for mechanistic purposes.
For instance, to investigate intestinal supersaturation and precipi-
tation of weakly basic drugs upon gastric emptying, it might be
advantageous to neglect gastric dissolution by administering drug
solutions directly into the stomach (Psachoulias et al., 2011). Fed
state conditions can be simulated by either a nutritional drink
(Brouwers et al., 2007a) or a homogenized liquid meal (Vertzoni
et al., 2012). It should be recognized that solid meals will have a
different effect on gastric motility, but they are incompatible with
aspiration studies (clogging of catheter).
3.3. Sampling and characterizing gastrointestinal fluids
Once the drug has been administered, gastrointestinal fluids are
manually aspirated as a function of time, typically in intervals of 5–
30 min during a period of 2–4 h. Immediately upon sampling, pre-
cautions should be taken to avoid any post-sampling alterations in
the aspirated fluids. Enzymatic digestion should be inhibited by
adding lipase and protease inhibitors, especially when investigat-
ing fed state conditions. In case of poorly soluble drugs, it is essen-
tial to separate non-dissolved and/or precipitated drug particles
(centrifugation or filtration) and to avoid possible further precipi-
tation by diluting the particle-free sample. Also for degradation-
sensitive drugs (enzymatic and/or chemical), the required precau-
tions should be taken. During handling, care should also be taken
to limit exposure to atmospheric CO2, since this may affect the
pH of the poorly buffered aspirates (Kalantzi et al., 2006; Perez
de la Cruz Moreno et al., 2006). Once the samples have been stabi-
lized, they can be stored prior to further analysis.
Quantification of drug concentrations in the aspirated fluids re-
quires validated bioanalytical assays employing common tech-
niques for sample preparation (typically protein precipitation or
extraction), compound separation (HPLC) and compound detection
(UV, fluorescence or MS/MS). Considering the high variability of
the composition of gastrointestinal fluids, the bioanalytical method
has to be robust against matrix effects. It should further be noted
that drugs dissolved in intestinal fluids can be present in multiple
colloidal phases, including a lipid phase and a water phase contain-
ing micelles and vesicles. Especially in fed state conditions, it may
be highly informative to utilize ultracentrifugation to separate at
least the lipid phase from the micelle-containing water phase, as
illustrated by Vertzoni et al. (2012).
Apart from drug concentrations, additional characteristics of
the aspirated fluids may be determined to further improve our
understanding of intraluminal formulation behavior. In case ofminal drug and formulation behavior: Gastrointestinal concentration pro-
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Fig. 2. Gastrointestinal fluid sampling following drug administration in humans to identify intraluminal processes determining drug absorption and to investigate the drug’s
permeation potential.
Fig. 3. Fluoroscopic image of the position of two double-lumen catheters in the
gastrointestinal tract of a healthy volunteer.
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istics of the precipitate have been assessed by means of X-ray pow-
der diffraction (XRPD) (Psachoulias et al., 2011) or Raman
microscopy (Bergman et al., 2007) since they may determine the
rate of redissolution. In addition, the aspirated fluids may be used
as donor media in in vitro permeation models (Brouwers et al.,
2006; Vertzoni et al., 2012). This gains highly relevant insight into
the complex process of drug permeation from intraluminal fluids.
Finally, fluid properties including pH, osmolality, viscosity, surface
tension, buffer capacity and concentration of bile salts, phospholip-
ids and dietary (digestion) products, may be determined for corre-
lation purposes.
With respect to the sampling of gastrointestinal fluids, it is
important to recognize that both the stomach and the upper smallPlease cite this article in press as: Brouwers, J., Augustijns, P. Resolving intralu
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Schiller et al., 2005). Although this may cause artefactual variabil-
ity in the concentration–time profiles, it did not compromise the
studies performed so far (see Section 4).
3.4. Relating intraluminal behavior to drug absorption
Gastrointestinal concentration–time profiles of orally adminis-
tered drugs reflect the interplay between multiple gastrointestinal
processes (transit, release, dissolution, precipitation, degradation
and mucosal permeation) and provide as such insight into the
intraluminal behavior of dosage forms. From a pragmatic point of
view, it is essential to identify those intraluminal processes and
variables that are key for drug absorption (and thus formulation
performance). This can be achieved by the simultaneous sampling
of gastrointestinal fluid and blood to correlate intraluminal and
systemic concentrations, as will be illustrated in the examples be-
low. Obviously, determining systemic drug concentrations only
makes sense if simultaneously aspirated volumes of gastric and
intestinal fluids are kept to a minimum, in order to minimize the
effect of drug sampling on the absorption process.4. Applications of gastrointestinal concentration profiling in
humans
Case studies presented in the following sections will demon-
strate how gastrointestinal drug concentration profiling has im-
proved our understanding of selected aspects of intraluminal
drug and formulation behavior in humans. Also the optimization
of in vitro simulation models based on this novel type of knowl-
edge will be illustrated.
4.1. Intraluminal solubilization and the solubility-permeability
interplay
The HIV protease inhibitor amprenavir is a lipophilic drug
(logP  2) with limited aqueous solubility (70 lg/ml or
0.14 mM at pH 6.5), especially in relation to the high required dose
(1200 mg). To enable absorption, the original amprenavir dosageminal drug and formulation behavior: Gastrointestinal concentration pro-
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amprenavir (1200 mg) predissolved in a mixture of cosolvents
and the surfactant d-a-tocopheryl polyethyleneglycol 1000
succinate (TPGS, 2240 mg). Following oral administration of this
formulation, Brouwers et al. (2006) collected duodenal and jejunal
fluids from healthy volunteers. Mean amprenavir concentrations in
the duodenum exceeded the solubilizing capacity of reference
intestinal fluid up to 30-fold (Fig. 4A), demonstrating significant
intraluminal solubilization. The main solubilizing excipient TPGS
was present at levels well above its critical micellar concentration
(0.13 mM) (Fig. 4B). In the jejunum (ca. 90 cm more distally), max-
imum amprenavir concentrations were about 70% lower than
those in the duodenum. In a similar study with an immediate re-
lease formulation of theophylline, the concentration drop from
duodenum to jejunumwas even larger (ca. 90%), suggesting a high-
er mucosal permeability for theophylline compared to amprenavir.
For the largely hydrophilic and less permeable excipient TPGS, on
the other hand, the concentration gradient between duodenum
and jejunum was clearly lower (Fig. 4B).
While intraluminal concentrations are the driving force for drug
permeation across the intestinal mucosa, the absorptive flux will
further be affected by the permeability of the mucosa for the drug.
In traditional formulation evaluation, in vitro-in vivo extrapola-
tions therefore combine in vitro dissolution data with the esti-
mated permeability for the active ingredient. This approach
largely ignores the influence of the highly complex composition
of intraluminal fluids on the drug’s permeability (Kostewicz
et al., in press). Obviously, intestinal concentration profiling upon
drug intake enables the assessment of biorelevant drug concentra-
tions for permeability estimation, which may be essential to eluci-
date the impact of transporters and enzymes on the absorption
process. In addition, the potential of the drug to permeate the
intestinal monolayer in relevant conditions may be evaluated
starting from the intestinal fluid aspirates (Fig. 2). In this respect,
intestinal fluid samples collected upon administration of amprena-
vir (diluted 1:1 with aqueous transport medium) were used as do-
nor in Caco-2 transport experiments (Brouwers et al., 2006). In
comparison with a plain aqueous solution of amprenavir, the intes-
tinal fluid samples affected the amprenavir flux in multiple ways.
Not only did the driving force for permeation increase as a result
of high amprenavir concentrations (Fig. 4), but also the permeabil-
ity was affected. Although bile salts and the excipient TPGS inhib-
ited P-glycoprotein-based efflux of amprenavir, the overall
permeability was decreased due to entrapment of amprenavir in
TPGS-based micelles (Brouwers et al., 2006). The latter effect illus-
trates the so-called solubility-permeability interplay: food- or
excipient-based strategies that enhance the solubility of lipophilic
drugs may decrease their permeability by reducing the drug’s par-
tition coefficient between the membrane and the intraluminal
medium. To account for these types of effects, there is a growingFig. 4. Concentration–time profiles of amprenavir (A) and the surfactant TPGS (B)
administration of a single dose of Agenerase (mean ± SD, n = 4). The dotted line on (A
(0.18 mM). Data from Brouwers et al. (2006) and Wuyts et al. (2013).
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ces into the in vitro evaluation of absorption-enabling strategies
(Kostewicz et al., in press). Intraluminal fluid sampling upon drug
intake may guide the development of such tools by providing ref-
erence media.
In this framework, Vertzoni et al. (2012) collected intestinal flu-
ids following the administration of the highly lipophilic drug dana-
zol predissolved in the oil portion of a heterogeneous liquid meal.
By ultracentrifugation of the luminal aspirates, the aqueous micel-
lar phase was separated from a lipid phase and an interphase. Sub-
sequently, permeation of danazol from diluted full aspirates and
diluted micellar phases was studied across Caco-2 monolayers.
Overall, danazol permeability decreased as a function of lipid con-
centration in the diluted samples (Fig. 5). In comparison with a
simple aqueous medium, danazol permeability was significantly
reduced when starting from diluted aspirates but not from diluted
micellar phases. It should be noted that effects on permeability
may be somewhat obscured due to the strong sample dilution (1/
16) needed to ensure monolayer integrity. In the aspirates, danazol
was mainly present in the lipid phase: on average, danazol concen-
trations were about 10-fold higher in the aspirates than in the cor-
responding micellar phases. Still, the high total concentrations in
the aspirates resulted in an enhanced danazol flux (thereby com-
pensating for the reduced permeability). This suggests that, at least
for danazol, the total concentration rather than the concentration
in the micellar phase, should be considered the main driving force
for permeation.
As illustrated above, the use of intestinal fluid samples aspi-
rated after drug administration provides a highly relevant means
of understanding the influence of intraluminal factors on drug per-
meation. However, the application of this approach is severely lim-
ited due to compatibility issues between the intestinal fluid and
cellular-based absorption models, including Caco-2 monolayers.
Usually, significant dilution is required to ensure monolayer integ-
rity (Vertzoni et al., 2012), which obviously compromises the rele-
vance of the obtained results. Approaches to increase the
robustness of cell-based permeation models are currently under
investigation (e.g. inclusion of mucus). Alternatively, tissue-based
ex vivo or in situ models may be used. In this respect, Holmstock
et al. (2013) successfully applied fasted and fed state human intes-
tinal fluid pools as donor medium during the in situ perfusion of
mice intestine to demonstrate reduced permeation of indinavir in
postprandial conditions.
4.2. Postprandial tablet disintegration
Fosamprenavir is a phosphate ester prodrug of amprenavir with
improved aqueous solubility. As compared to the original, solubi-
lizing formulation of amprenavir, immediate release tablets of
fosamprenavir (Telzir) significantly reduce the pill burden for pa-in duodenal and jejunal fluid aspirates from healthy volunteers following oral
) represents the mean solubility of amprenavir in reference human intestinal fluid
minal drug and formulation behavior: Gastrointestinal concentration pro-
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Fig. 5. Permeability of Caco-2 monolayers for the lipophilic drug danazol from
intestinal fluid aspirates (squares) and their micellar phases (diamonds) as a
function of the corresponding total lipid concentration. Aspirates were collected
after administering a tryglyceride solution of danazol to healthy volunteers. Open
symbols refer to 1:16 diluted samples; closed symbols refer to other dilutions. The
total lipid concentration refers to the sum of tri-, di- and monoglycerides, fatty
acids, phosphatidylcholine, lysophosphatidylcholine and cholesterol. Reprinted
with permission from Vertzoni et al. (2012). Copyright 2012 American Chemical
Society.
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the uptake of amprenavir from fosamprenavir tablets: postprandial
intake of fosamprenavir strongly delayed the onset of amprenavir
absorption. For instance, upon intake of fosamprenavir with a
nutritional drink, mean tmax increased 2.5 h as compared to the
fasted state, without further affecting the rate or extent of absorp-
tion. Based on in vitro studies (Brouwers et al., 2007b), we hypoth-
esized that increased phosphate concentrations in fed state
conditions would inhibit the intestinal dephosphorylation of
fosamprenavir, required for transepithelial permeation. To test this
hypothesis in vivo, gastrointestinal fluids and plasma samples
were simultaneously collected from healthy volunteers upon
administration of a fosamprenavir tablet in fasted and fed state
(Brouwers et al., 2007a). However, the clinical study revealed that,
instead of dephosphorylation, the preceding duodenal appearance
of fosamprenavir determined the onset of absorption and plasma
tmax. The strong correlation between individual plasma tmax-values
of amprenavir and duodenal tmax-values of fosamprenavir is de-
picted in Fig. 6. In fed state conditions, not only duodenal appear-
ance but also gastric dissolution of fosamprenavir appeared to be
postponed as a result of an unexpected delay in gastricFig. 6. Correlation between individual plasma tmax-values of amprenavir and
corresponding duodenal tmax-values of fosamprenavir following oral administration
of a single Telzir tablet to healthy volunteers in fasted and fed state. Data from
Brouwers et al. (2007a).
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confirmed impaired water ingress into the HPMC-coated fosam-
prenavir tablets in the presence of a nutritional drink (Brouwers
et al., 2011), causing the immediate release tablet to behave as
an enteric-coated dosage form in the postprandial stomach. From
Fig. 6, it is interesting to note that not only the food-induced delay
in amprenavir absorption but also the relatively high interindivid-
ual variations can be explained by differences in duodenal appear-
ance of fosamprenavir. Overall, this study nicely demonstrates how
the combination of gastrointestinal and systemic concentration
profiling may assist in identifying intraluminal processes that
determine absorption. In addition, the clinical data were used as
reference to validate the TNO Intestinal Model (TIM-1) for evalua-
tion of food-dependent disintegration of immediate release tablets
(Brouwers et al., 2011). It appeared that TIM-1 could not only pre-
dict the impaired disintegration as such but also the impact on
absorption (affecting the onset but not the extent of absorption).4.3. The role of acidic beverages in the gastric dissolution of weakly
basic drugs
A significant number of drugs and drug candidates are poorly
water soluble weak bases. As a result of their ionization behavior,
intestinal absorption often relies on dissolution in the acidic envi-
ronment of the fasted state stomach. Elevated gastric pH due to, for
instance, hypochloridia or the use of proton pump inhibitors (PPIs),
may therefore compromise absorption of this type of drugs. This
behavior has been confirmed by gastrointestinal concentration
profiling for the antifungal drug posaconazole (Walravens et al.,
2011). Upon co-administration of the oral suspension of posaco-
nazole (Noxafil) with the PPI esomeprazole, the elevated gastric
pH resulted in significantly lower gastric posaconazole concentra-
tions and reduced absorption. Simultaneous intake of an acidic
beverage (Coca-Cola) was not sufficient to completely restore
the reduced posaconazole absorption, since the beverage could
only partly compensate for the PPI-induced increase in gastric pH
and decrease in posaconazole dissolution. Remarkably, posaconaz-
ole absorption was also significantly enhanced by intake with an
acidic beverage in normal conditions (i.e. without PPI administra-
tion). The gastric concentration profiles revealed enhancement of
posaconazole dissolution following intake with the acidic beverage
instead of water; in contrast to the usually accepted hypothesis,
however, this could not be attributed to an effect on the gastric
pH, in contrast to the usually accepted. From Fig. 7, it is obvious
that the beverage prolonged the dissolution time window for posa-Fig. 7. Gastric concentration–time profiles of the lipophilic and weakly basic drug
posaconazole following administration of the oral suspension Noxafil to healthy
volunteers. Posaconazole was administered in the fasted state with either water
(circles) or the acidic beverage Coca-Cola (squares). The inset figure displays the
corresponding gastric pH as a function of time. Data (mean ± SD, n = 5) from
Walravens et al. (2011).
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idence time.
4.4. Intestinal supersaturation and precipitation of weakly basic drugs
As already mentioned in the introduction, predicting intralumi-
nal precipitation of drugs is currently one of the main hurdles in
the design of so-called supersaturating drug delivery systems to
overcome solubility-limited absorption (Bevernage et al., 2013).
A few recent papers describe the use of intraluminal concentration
profiling to shed light on the influence of gastrointestinal physiol-
ogy on drug precipitation. Poorly soluble weak bases are the pre-
ferred model drugs, since intestinal supersaturation may simply
occur upon transfer from the stomach (low pH and high solubility)
to the intestine (higher pH and lower solubility).
A first attempt to investigate intestinal precipitation in humans
involved the administration of a dispersion of the weak base gefin-
itib in the stomach followed by sampling of jejunal fluid using the
Loc-I-Gut catheter (Bergman et al., 2007). The study could not re-
late differences in pharmacokinetics among the tested volunteers
with the observed intraluminal behavior. In addition, the study
was not able to distinguish between undissolved and precipitated
drug. Although jejunal samples were analyzed with Raman spec-
troscopy, the solid state properties could not be determined due
to interference with the complex nature of the fluids.
To avoid issues with incomplete gastric dissolution, Psachoulias
et al. (2011) administered solutions of the weakly basic and lipo-
philic drugs ketoconazole and dipyridamole to investigate intesti-
nal precipitation. By determining not only the drug concentration
but also the drug’s equilibrium solubility in the aspirated intestinal
fluids, the authors were able to demonstrate supersaturation of the
weak bases for up to 30 min (dipyridamole) and 50 minFig. 8. Case study indicating intestinal precipitation of posaconazole, a poorly water so
concentrations upon oral administration of the posaconazole suspension Noxafil to hea
samples of a representative volunteer. (C) Physiologically based modeling (ADAM mo
Reprinted with permission from Brouwers and Augustijns (2011). Data (A and B) from W
Please cite this article in press as: Brouwers, J., Augustijns, P. Resolving intralu
filing in humans. Eur. J. Pharm. Sci. (2014), http://dx.doi.org/10.1016/j.ejps.201(ketoconazole) post-dosing. Only limited luminal precipitation
was observed: compared to the total drug amount in the intestinal
samples, the fraction of precipitated drug amounted to maximum
7% for dipyridamole and maximum 16% for ketoconazole. Using
XRPD analysis of the aspirated ketoconazole precipitates, 3 differ-
ent solid states were identified: 2 crystalline forms and 1 amor-
phous form as the most abundant one. Interestingly, a classic
two-compartmental in vitro transfer model (Kostewicz et al.,
2004) that has been designed by only considering systemic con-
centration data as reference, significantly overestimated the ob-
served intestinal precipitation of dipyridamole and ketoconazole
in humans. Therefore, Psachoulias et al. (2012) developed an opti-
mized in vitro model based on the observed in vivo intraluminal
data. To predict the intraluminal concentrations and to reduce
in vitro precipitation, it appeared crucial to simulate drug disap-
pearance from the duodenal compartment (due to intestinal transit
and absorption of the highly permeable drugs) by implementing an
outgoing flow and a reservoir compartment with concentrated bio-
relevant intestinal medium. Additional variables that were opti-
mized for improved predictive power included the flow rates
between the compartments, the applied hydrodynamics and the
composition of simulating intestinal fluid. This setup for simulat-
ing the in vitro behavior of poorly soluble and highly permeable
weak bases is one of the first in vitro models for which the devel-
opment was guided by intraluminal rather than systemic in vivo
data.
Similar to ketoconazole and dipyridamole, posaconazole is a
weakly basic drug with poor solubility and high permeability. In
the above-mentioned study on the intraluminal behavior of the
posaconazole suspension Noxafil (Section 4.2) not only gastric
but also intestinal fluids were aspirated (Walravens et al., 2011).
In the duodenal samples, most posaconazole was present in solidluble and weakly basic drug, in man. (A) Mean gastric and duodenal posaconazole
lthy volunteers (fasted state). (B) Total versus dissolved posaconazole in intestinal
del) of the influence of precipitation on duodenal posaconazole concentrations.
alravens et al. (2011).
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solved or precipitated particles. In addition, intestinal posaconaz-
ole concentrations were extremely low (at least 5- to 10-fold
lower than gastric concentrations, Fig. 8A). In an attempt to eluci-
date the potential role of precipitation, PBPK sensitivity analysis
was performed (ADAM model), using relevant posaconazole
parameters (gastric concentrations and high permeability) and
varying precipitation rates as input, and duodenal concentrations
as output (Brouwers and Augustijns, 2011). The modeling revealed
that only the assumption of extensive posaconazole precipitation
was in agreement with the low concentrations measured in hu-
mans (Fig. 8C). Most likely, the difference in precipitation between
posaconazole (extensive) and dipyridamole/ketoconazole (limited)
can be attributed to the difference in dosing (suspension versus
solution). In case of administering a suspension, incomplete gastric
dissolution may cause undissolved particles to be transferred to
the intestine where they can act as nuclei for precipitation.5. Concluding remarks
In contrast to systemic concentrations, gastrointestinal drug
concentrations following oral administration directly reflect the
intraluminal events that dictate absorption. The multitude of pro-
cesses involved, combined with the highly fluctuating intraluminal
environment, makes it challenging to interpret gastrointestinal
concentration-time profiles. Nevertheless, the case studies dis-
cussed in this review demonstrate the added value of gastrointes-
tinal concentration profiling in resolving poorly understood
intraluminal processes, including precipitation and permeation
from complex matrices. The combination with simultaneous sys-
temic concentration assessment further helps to identify those
processes determining the rate and/or extent of absorption, as well
as inter-individual variability. Now that gastrointestinal concen-
tration profiling has been established as a novel tool to evaluate
intraluminal drug and formulation behavior in humans, intensified
use can be expected to guide the optimization of simulation mod-
els for drug absorption. This is, for instance, manifested within the
new European OrBiTo initiative that pursues the development of
physiologically relevant models, supported by a solid understand-
ing of the underlying processes. Especially for challenging drug
candidates (low solubility and/or permeability) that rely on com-
plex enabling strategies (e.g. solubilization, supersaturation), such
models will allow for improved prediction of in vivo performance.
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